Q32 Bio Inc. (LON: 0T6G)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 34.02M |
| Revenue (ttm) | -10.94M |
| Net Income (ttm) | -45.22M |
| Shares Out | n/a |
| EPS (ttm) | -4.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 603 |
| Average Volume | 8,863 |
| Open | 3.390 |
| Previous Close | 3.391 |
| Day's Range | 3.270 - 3.428 |
| 52-Week Range | 0.458 - 3.428 |
| Beta | n/a |
| RSI | 24.76 |
| Earnings Date | Mar 28, 2025 |
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy... [Read more]
News
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
On Wednesday, Q32 Bio Inc. (NASDAQ: QTTB) revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA) . The company plans to ex...
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?
On Wednesday, Q32 Bio Inc. QTTB revealed topline results from the SIGNAL-AA Phase 2a signal finding trial evaluating bempikibart (ADX-914) for alopecia areata (AA).
Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low.
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 re...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials expected in December -- -- Enrollment ongoing in...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,...
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued cli...
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis...
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of loc...
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
The United States' macroeconomic environment was favorable to large-cap companies and unfriendly to small-caps through the first half of 2024. That changed in July.
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
-- Exceeded enrollment target due to patient demand; trial size increased to 121 patients -- -- Bempikibart topline results remain on track to be released in Q4'24 -- WALTHAM, Mass. , July 9, 2024 /PR...
Q32 Bio Joins Russell 3000® Index
WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,...
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial rema...
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
WALTHAM, Mass. , April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis...
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
-- Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinical...